Dr.K. Mahalakshmi M.D(PATH)


Introduction: Ovarian cancer is a common malignancy in Indian women and it ranks third in women globally.Germ cell tumours are a group of
ovarian tumours affecting young age that respond very well to chemo and radiotherapy.Tumors that are positive for CD117 marker have treatment
in the form of imatinib. Present study was done to look at the rate of positivity of CD117 in malignant germ cell tumors and especially
Aim of the study: To study the histo-morphological features of ovarian tumors with emphasis on germ cell tumours including tumour size,
macroscopic appearance, histological type, grade, stage and to study the immunohistochemical expression of CD117 in germ celltumours of ovary,
particularly in dysgerminomas.
Materials and methods: This was a prospective study done in the Institute of Pathology and Electron Microscopy,Madras Medical College and
Rajiv Gandhi Government General Hospital, Chennai,over a five year nine months period.The ovarian tumors were studied for light microscopy.
Immunohistochemistry for CD117 was done in malignant germ cell tumors and it was correlated for patient age, histologic type, grade and stage of
Results: Surface epithelial tumors (75.5%) were most common followed by germ cell tumors(GCT) (16.5%).In the malignant GCT, 11 (36.6%)
were dysgerminomas.The mean age for malignant GCT was 22.4 yearsand the average size was 15.7 cm.The immunohistochemicalexpression of
C-kit was more in pure dysgerminoma (90.9%) than other malignant GCT but the correlation was not statistically significant.


C-kit expression, Ovariantumors, Dysgerminomas

Full Text:



Murthy NS,Shalini S, Suman G, Pruthvish S, Mathew A. Changing Trends in the Incidence of Ovarian Cancer in India. Asian Pacific J Cancer Prev 2009;10,:1025-1030

Parkin DM, Muir CS, Whelan SL, Gao YT, FerlayJ, Powell J. (eds) (1992). Cancer Incidence in Five Continents, Vol. VI, International Agency for Research on Cancer, Lyon, France, IARC Scientific Publication No. 143

Vliagoftis H, Worobec AS, Metcalfe DD. The proto oncogene c-kit and c-kit ligand in human disease. J Allergy ClinImmunol 1997;100:435–440.

Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003;98:758–764.

Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003;63:7674–7678.

Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003;39:793–799.

Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992;52:713–717.

Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pasha TL, et al. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int J GynecolPathol 2003;22:149–155.

Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O’Meara AT, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. GynecolOncol 2003;90:402–406.

Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, et al. C-kit expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 2005;18:320–323

Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98:241–243.

Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, et al. Association of KIT exon 9 mutations with non- gastric primary site and aggressive behaviour: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329–3337.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, etal.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–1056.

Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, perdichizzi S, et al. C-kit receptor expression in Ewing‘s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J ClinOncol 2003;21:1952–1960.

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96: 925–932.

Cheng L, Roth LM, Zhang S, Wang M, Morton MJ, Zheng W, et al. KIT Gene Mutation and Amplification in Dysgerminoma of the Ovary. Cancer 2011;117:2096–103.

Ahmad Z, Kayani N, Hasan SH, Muzaffar S, Gill MS. Histological pattern of ovarian neoplasm. J Pak Med Assoc 2000;50: 416-9.

Pilli GS, Suneeta KP, Dhaded AV, Yenni VV. Ovarian tumours:a study of 282 cases. JIndian Med Assoc2002; 100: 420,423-4, 447

Gupta N, Bisht D, Agarwal AK, Sharma VK. Retrospective and prospective study of ovarian tumors and tumor like lesions. Indian J PatholMicrobiol 2007; 50: 525-7.

Jha R, Karki S. Histological pattern of ovarian tumours and their age distribution. Nepal Med Coll J 2008; 10: 81-5.

Pradhan A, Sinha AK, Upreti D. Histopathological patterns of ovarian tumors at BPKIHS. 2012;10(2);87-97.

Swamy GG, Satyanarayana N. Clinicopathological analysis of ovarian tumors – A study on five years samples Nepal Med Coll J 2010; 12(4):221- 223.

Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, Wootipoom V, Thavaramara T, Buhachat R et al. Malignant ovarian germ cell tumors: Clinico-pathological Presentation and survival outcomes ActaObstetricia et Gynecologica. 2010;89:182–189.

Chow SN, Yang JH, Lin YH, Chen YP, Lai JI, Chen RJ, et al. Malignant ovarian germ cell tumors. Int J GynaecolObstet 1996;53:151–8.

Chyong HL, Chang TC, Hsueh S, Wu TI, Chao A, Chou HH, et al. Outcome and Prognostic Factors in Ovarian Germ Cell Malignancies. Journal of Gynecologic Oncology 2005;60(6);364-365.

Trinh DT, Shibata K, Hirosawa T, Umezu T, Mizuno M, Kajiyama H, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. J ObstetGynaecol Res. 2012;38(5):841-8.

Sever M, Jones YD, Roth LM, Karim FAW, Zheng W, Michael H, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Modern Pathology 2005;18:1411–1416.

Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424: 135–141.

Sakuma Y, Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K. C-kit gene mutations in intracranial germinomas. Cancer Sci 2004; 95:716–720.


  • There are currently no refbacks.